These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 32838755)

  • 41. Replication DNA polymerases, genome instability and cancer therapies.
    Strauss JD; Pursell ZF
    NAR Cancer; 2023 Sep; 5(3):zcad033. PubMed ID: 37388540
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Validation of computational determination of microsatellite status using whole exome sequencing data from colorectal cancer patients.
    Johansen AFB; Kassentoft CG; Knudsen M; Laursen MB; Madsen AH; Iversen LH; Sunesen KG; Rasmussen MH; Andersen CL
    BMC Cancer; 2019 Oct; 19(1):971. PubMed ID: 31638937
    [TBL] [Abstract][Full Text] [Related]  

  • 43. POLE gene hotspot mutations in advanced pancreatic cancer.
    Guenther M; Veninga V; Kumbrink J; Haas M; Westphalen CB; Kruger S; Heinemann V; Kirchner T; Boeck S; Jung A; Ormanns S
    J Cancer Res Clin Oncol; 2018 Nov; 144(11):2161-2166. PubMed ID: 30194485
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Human Pol ε-dependent replication errors and the influence of mismatch repair on their correction.
    Agbor AA; Göksenin AY; LeCompte KG; Hans SH; Pursell ZF
    DNA Repair (Amst); 2013 Nov; 12(11):954-63. PubMed ID: 24051051
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study.
    Domingo E; Freeman-Mills L; Rayner E; Glaire M; Briggs S; Vermeulen L; Fessler E; Medema JP; Boot A; Morreau H; van Wezel T; Liefers GJ; Lothe RA; Danielsen SA; Sveen A; Nesbakken A; Zlobec I; Lugli A; Koelzer VH; Berger MD; Castellví-Bel S; Muñoz J; ; de Bruyn M; Nijman HW; Novelli M; Lawson K; Oukrif D; Frangou E; Dutton P; Tejpar S; Delorenzi M; Kerr R; Kerr D; Tomlinson I; Church DN
    Lancet Gastroenterol Hepatol; 2016 Nov; 1(3):207-216. PubMed ID: 28404093
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Chimeric thermostable DNA polymerases with reverse transcriptase and attenuated 3'-5' exonuclease activity.
    Schönbrunner NJ; Fiss EH; Budker O; Stoffel S; Sigua CL; Gelfand DH; Myers TW
    Biochemistry; 2006 Oct; 45(42):12786-95. PubMed ID: 17042497
    [TBL] [Abstract][Full Text] [Related]  

  • 47. POLE mutations in families predisposed to cutaneous melanoma.
    Aoude LG; Heitzer E; Johansson P; Gartside M; Wadt K; Pritchard AL; Palmer JM; Symmons J; Gerdes AM; Montgomery GW; Martin NG; Tomlinson I; Kearsey S; Hayward NK
    Fam Cancer; 2015 Dec; 14(4):621-8. PubMed ID: 26251183
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Distinct clinical pattern of colorectal cancer patients with POLE mutations: A retrospective study on real-world data.
    Jiang M; Jia Y; Han J; Shi J; Su C; Zhang R; Xing M; Jin S; Zong H
    Front Genet; 2022; 13():963964. PubMed ID: 36479248
    [No Abstract]   [Full Text] [Related]  

  • 49. Immunological profiling of molecularly classified high-risk endometrial cancers identifies
    Eggink FA; Van Gool IC; Leary A; Pollock PM; Crosbie EJ; Mileshkin L; Jordanova ES; Adam J; Freeman-Mills L; Church DN; Creutzberg CL; De Bruyn M; Nijman HW; Bosse T
    Oncoimmunology; 2017; 6(2):e1264565. PubMed ID: 28344870
    [TBL] [Abstract][Full Text] [Related]  

  • 50. POLE exonuclease domain mutations in endometrial carcinoma: a case report.
    Pasciuto MP; Felicioni L; Zampacorta C; Ferro B; Di Marino P; Primavera FC; Lucidi A; Rossetti R; Barbareschi M; Marchetti A; Buttitta F; D'Angelo E
    Pathologica; 2023 May; 1(1):181-185. PubMed ID: 37216304
    [TBL] [Abstract][Full Text] [Related]  

  • 51. First description of ultramutated endometrial cancer caused by germline loss-of-function and somatic exonuclease domain mutations in POLE gene.
    Rosa RCA; Yurchenko AA; Chahud F; Ribeiro-Silva A; Brunaldi MO; Silva WA; Kannouche PL; Nikolaev S; Ferraz VEF
    Genet Mol Biol; 2020; 43(4):e20200100. PubMed ID: 33001133
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Ratio of 3' --> 5'-exonuclease and DNA-polymerase activities in normal and cancer cells of rodents and humans].
    Kravetskaia TP; Ronzhina NL; Krutiakov VM
    Tsitologiia; 2010; 52(8):634-8. PubMed ID: 20968097
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Morphological, immunophenotypical and molecular features of hypermutation in colorectal carcinomas with mutations in DNA polymerase ε (POLE).
    Forgó E; Gomez AJ; Steiner D; Zehnder J; Longacre TA
    Histopathology; 2020 Feb; 76(3):366-374. PubMed ID: 31479159
    [TBL] [Abstract][Full Text] [Related]  

  • 54. POLE somatic mutations in advanced colorectal cancer.
    Guerra J; Pinto C; Pinto D; Pinheiro M; Silva R; Peixoto A; Rocha P; Veiga I; Santos C; Santos R; Cabreira V; Lopes P; Henrique R; Teixeira MR
    Cancer Med; 2017 Dec; 6(12):2966-2971. PubMed ID: 29072370
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Germline PMS2 and somatic POLE exonuclease mutations cause hypermutability of the leading DNA strand in biallelic mismatch repair deficiency syndrome brain tumours.
    Andrianova MA; Chetan GK; Sibin MK; Mckee T; Merkler D; Narasinga RK; Ribaux P; Blouin JL; Makrythanasis P; Seplyarskiy VB; Antonarakis SE; Nikolaev SI
    J Pathol; 2017 Nov; 243(3):331-341. PubMed ID: 28805995
    [TBL] [Abstract][Full Text] [Related]  

  • 56. DNA polymerase theta up-regulation is associated with poor survival in breast cancer, perturbs DNA replication, and promotes genetic instability.
    Lemée F; Bergoglio V; Fernandez-Vidal A; Machado-Silva A; Pillaire MJ; Bieth A; Gentil C; Baker L; Martin AL; Leduc C; Lam E; Magdeleine E; Filleron T; Oumouhou N; Kaina B; Seki M; Grimal F; Lacroix-Triki M; Thompson A; Roché H; Bourdon JC; Wood RD; Hoffmann JS; Cazaux C
    Proc Natl Acad Sci U S A; 2010 Jul; 107(30):13390-5. PubMed ID: 20624954
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A single aspartate mutation in the conserved catalytic site of Rev3L generates a hypomorphic phenotype in vivo and in vitro.
    Fritzen R; Delbos F; De Smet A; Palancade B; Canman CE; Aoufouchi S; Weill JC; Reynaud CA; Storck S
    DNA Repair (Amst); 2016 Oct; 46():37-46. PubMed ID: 27481099
    [TBL] [Abstract][Full Text] [Related]  

  • 58. POLE proofreading defects: Contributions to mutagenesis and cancer.
    Park VS; Pursell ZF
    DNA Repair (Amst); 2019 Apr; 76():50-59. PubMed ID: 30818169
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prognostic significance of POLE proofreading mutations in endometrial cancer.
    Church DN; Stelloo E; Nout RA; Valtcheva N; Depreeuw J; ter Haar N; Noske A; Amant F; Tomlinson IP; Wild PJ; Lambrechts D; Jürgenliemk-Schulz IM; Jobsen JJ; Smit VT; Creutzberg CL; Bosse T
    J Natl Cancer Inst; 2015 Jan; 107(1):402. PubMed ID: 25505230
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A Phase II Study of Avelumab Monotherapy in Patients with Mismatch Repair-Deficient/Microsatellite Instability-High or POLE-Mutated Metastatic or Unresectable Colorectal Cancer.
    Kim JH; Kim SY; Baek JY; Cha YJ; Ahn JB; Kim HS; Lee KW; Kim JW; Kim TY; Chang WJ; Park JO; Kim J; Kim JE; Hong YS; Kim YH; Kim TW
    Cancer Res Treat; 2020 Oct; 52(4):1135-1144. PubMed ID: 32340084
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.